Attached files
| file | filename |
|---|---|
| EX-99.2 - PHARMACYCLICS INC | ex992to8k07380004_07282014.htm |
| EX-99.1 - PHARMACYCLICS INC | ex991to8k07380004_07282014.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 28, 2014
|
PHARMACYCLICS, INC.
|
||
|
(Exact name of registrant as specified in its charter)
|
||
|
Delaware
|
000-26658
|
94-3148201
|
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
|
995 E. Arques Avenue, Sunnyvale, California
|
94085-4521
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
|
Registrant’s telephone number, including area code: (408) 774-0330
|
|
|
(Former name or former address, if changed since last report.)
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 7.01.
|
Regulation FD Disclosure.
|
On July 28, 2014, Pharmacyclics, Inc. (the “Company”) issued a press release and hosted a conference call to discuss the Company’s announcement that the U.S. Food and Drug Administration has granted IMBRUVICA® (ibrutinib) regular (full) approval for the treatment of patients with chronic lymphocytic leukemia (“CLL”) who have received at least one prior therapy, and for the treatment of CLL patients with deletion of the short arm of chromosome 17 (“del 17p CLL”), including treatment naive and previously treated del 17p CLL patients. The foregoing description is qualified in its entirety by reference to the July 28, 2014 Conference Call Transcript and the Press Release dated July 28, 2014, copies of which are attached hereto as Exhibits 99.1 and 99.2, respectively and are incorporated herein by reference.
The information in this Current Report on Form 8-K and the Exhibits 99.1 and 99.2 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference into any of the Registrant's filings under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.
|
Item 9.01
|
Financial Statements and Exhibits.
|
|
|
(d)
|
Exhibits.
|
|
Exhibit No.
|
Description
|
|
99.1
|
July 28, 2014 Conference Call Transcript
|
|
99.2
|
Press Release dated July 28, 2014
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.
July 30, 2014
|
PHARMACYCLICS, INC.
|
|
|
By:
|
/s/ Manmeet Soni
|
|
Name: Manmeet Soni
|
|
|
Title: Chief Financial Officer
|
|
EXHIBIT INDEX
|
Exhibit No.
|
Description
|
|
99.1
|
July 28, 2014 Conference Call Transcript
|
|
99.2
|
Press Release dated July 28, 2014
|